[Perspectives] Medical crowdfunding to access CAR T-cell therapy

Leggi l'articolo originale


US Food and Drug Administration (FDA) approval of two chimeric antigen receptor T (CAR T) cell therapies —tisagenlecleucel and axicabtagene ciloleucel—in 2017 offered new therapeutic options to paediatric patients with relapsed or refractory acute lymphoblastic leukaemia and adult patients with relapsed or refractory diffuse large B-cell lymphoma. These therapies, which have now been approved by regulatory bodies around the world, provide hope to patients who have few other available options, but these therapies raise important ethical concerns.

Lascia un commento